Måndag 13 Oktober | 22:13:37 Europe / Stockholm

Prenumeration

2025-10-03 11:41:00

Curasight has further strengthened the patent protection of its diagnostic platform uTRACE® with the grant of a new US patent. The patent extension adds just over two years of additional exclusivity, extending protection until 2035, and provides an extra layer of security around the company’s proprietary cancer imaging technology. We reached out to the CEO, Ulrich Krasilnikoff, for a comment.

Read the full interview at biostock.se:

Curasight strengthens the value of uTRACE with new US patent
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/